+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.

Age: 18Years +All GendersPhase 3
42 locations
P

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.

Age: 18Years +All GendersPhase 3
53 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of expanded dosing schedules of Xywav in adults with narcolepsy or idiopathic hypersomnia IH. This Phase 3 trial compares different dosing regimens of Xywav to placebo to better understand treatment options for these sleep disorders. The study is sponsored by Jazz Pharmaceuticals and focuses on adult participants aged 18 to 75 years. Participants will undergo three treatment phases an open-label titration and optimization period OL-TOP lasting up to 12 weeks to establish a stable dose of Xywav, followed by a stable dose period SDP of 2 weeks where they continue the stable dose. Finally, participants enter a double-blind randomized withdrawal period DBRWP for 2 weeks, where they are randomly assigned to continue their Xywav dose or switch to placebo. The expanded dosing regimens include once-nightly or twice-nightly doses based on prior treatment and investigator decision. Total treatment duration can be up to 16 weeks. During the trial, participants will be regularly assessed for sleepiness using the Epworth Sleepiness Scale and other sleep-related measures. Researchers will also monitor cataplexy frequency, sleep quality, and symptom severity through questionnaires and clinical evaluations. Safety will be tracked by recording adverse events. Participants will be closely followed throughout the treatment periods, with outcome measures taken at the end of each phase to evaluate the effects of the expanded dosing regimens.

Age: 18Years - 75YearsAll GendersPhase 3
15 locations
E

Actively Recruiting

Researchers are evaluating the drug Galvokimig compared to a placebo to see how it affects the time until the first acute worsening exacerbation of chronic obstructive pulmonary disease COPD in people with moderate-to-severe COPD who also have chronic bronchitis. This Phase 2 study focuses on participants aged 40 to 80 with a history of COPD exacerbations and chronic bronchitis symptoms. Participants are randomly assigned to receive one of two predefined doses of Galvokimig or a matching placebo. The study treatment is given as a solution for injection over a period ranging from 24 to 52 weeks. The purpose is to assess the drugs effect on reducing the frequency and timing of COPD exacerbations during this treatment phase. During the study, participants will be monitored regularly to measure lung function, quality of life related to respiratory health, and the number and severity of COPD exacerbations. Safety is closely followed by tracking adverse events up to 60 weeks. The main outcome is the time until the first moderate or severe COPD exacerbation, with additional assessments including lung function tests and patient questionnaires. Total study participation may last up to about 60 weeks.

Age: 40Years - 80YearsAll GendersPhase 2
23 locations
E

Actively Recruiting

Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.

Age: 12Years +All GendersPhase 2
186 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.

Age: 12Years - 80YearsAll GendersPhase 3
134 locations
R

Actively Recruiting

This research aims to evaluate the safety, tolerability, and effects of cleminorexton, a drug designed to mimic orexin, in people with Narcolepsy Type 1 NT1 and Narcolepsy Type 2 NT2, which cause excessive daytime sleepiness. It studies how cleminorexton impacts symptoms like sleepiness and cataplexy, a sudden loss of muscle strength seen in NT1, to learn more about its effects on these rare sleep disorders. Participants will be randomly assigned to one of several groups receiving either two different doses of cleminorexton or a matching placebo. The study includes separate groups for NT1 and NT2. Treatment consists of oral capsules taken during the trial, which lasts for 12 weeks. The study may expand in the future to include participants with idiopathic hypersomnia under a protocol amendment. During the study, participants will undergo regular assessments including sleep latency tests, sleepiness scales, cataplexy rate tracking, and other narcolepsy severity measures. Safety will be monitored through laboratory tests, vital signs, ECGs, and suicide risk assessments. Pharmacokinetic measurements of the drug will also be collected. The total participation duration includes baseline and 12-week treatment evaluations.

Age: 18Years - 70YearsAll GendersPhase 2Phase 3
26 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
S

Actively Recruiting

Researchers are investigating the effects and safety of the medicine PF-07275315 for treating moderate to severe Chronic Obstructive Pulmonary Disease COPD, a lung condition that makes breathing difficult and impacts daily life. This interventional study involves adults aged 35 to 80 who have had COPD for at least 12 months and experienced at least two moderate or severe exacerbations in the past year while on stable maintenance treatment. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections at the clinic. The Phase 2 portion lasts 24 weeks with study involvement totaling about 40 weeks and includes 11 clinic visits. The Phase 3 portion lasts 52 weeks with approximately 68 weeks total involvement and 18 clinic visits. The study compares outcomes between those receiving PF-07275315 and those receiving placebo to evaluate safety and effectiveness. During the study, participants will undergo regular assessments including lung function tests such as forced expiratory volume FEV1, monitoring of exacerbation rates, symptom questionnaires, safety lab tests, electrocardiograms, and vital signs. Safety and adverse events will be closely tracked throughout the study, and participants will be followed for the full duration of their assigned phase to monitor changes and outcomes related to COPD.

Age: 35Years - 80YearsAll GendersPhase 2Phase 3
189 locations
R

Actively Recruiting

Researchers are studying the effects of two doses of the drug EXPD-101FXS7553 in adults with Chronic Obstructive Pulmonary Disease COPD. This Phase 2 trial aims to assess how well the drug works, its safety, how well participants tolerate it, and how the body processes it. Participants will be adults aged 40 to 85 years with a confirmed diagnosis of COPD and a history of chronic bronchitis and exacerbations. Participants will be randomly assigned to one of three groups one receiving Dose 1 of EXPD-101FXS7553, another receiving Dose 2 of the same drug, or a third group receiving a placebo. All treatments are given as oral tablets once daily for 52 weeks. The study is double-blinded, meaning neither participants nor researchers know who is receiving the drug or placebo during the treatment period. During the study, participants will attend regular visits for assessments including lung function tests, questionnaires about respiratory symptoms and quality of life, physical exams, vital signs, and electrocardiograms. Researchers will monitor for moderate and severe COPD exacerbations and any adverse events throughout the 52 weeks. Blood and sputum samples will be collected at various points to study drug levels and biological effects. The overall goal is to understand the drugs impact on COPD symptoms and safety over a year-long treatment period.

Age: 40Years - 85YearsAll GendersPhase 2
35 locations